MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive ...

AGC Biologics offers a comprehensive suite of services for mammalian-based drug production, from cell line development to commercial manufacturing, enabling partners to accelerate their drug ...

COPENHAGEN, Denmark & CHIBA, Japan, May 06, 2025--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a multiphase partnership with Novelty Nobility Inc., a clinical-stage ...

COPENHAGEN, Denmark & CHIBA, Japan, May 06, 2025--(BUSINESS WIRE)--AGC Biologics, your friendly CDMO expert, today announced a multiphase partnership with Novelty Nobility Inc., a clinical-stage ...

Phoenix Equity Partners has promoted one of its co-founders to co-lead the business as part of a shake-up within its senior ranks. The UK growth-focused private equity firm told Private Equity News ...

The partnership will prepare for Phase I preparations for Novelty Nobility’s bispecific antibody drug candidate.

NBPE invests in direct private equity investments alongside market leading private equity firms globally. NB Alternatives Advisers LLC (the “Investment Manager”), an indirect wholly owned ...

David Gentile and Jeffry Schneider orchestrated a $1.8 billion private-equity operation likened to a Ponzi scheme.

which is backed by 65 Equity Partners, has completed the acquisition of Cerbios-Pharma. HAS is a developer and producer of active pharmaceutical ingredients, high-potency active pharmaceutical ...

NEW YORK--(BUSINESS WIRE)--Cantor Equity Partners II, Inc. (Nasdaq: CEPT) (the “Company”) announced today that it closed its initial public offering of 24,000,000 Class A ordinary shares at $ ...

VistaOne is an evergreen investment vehicle providing direct and continuous access to the full suite of Vista's private equity strategies VistaOne offers fully drawn exposure to direct deals with ...